Skip to content

Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5)

Sentinel Lymph Node Assessment In Ovarian Cancer - Turkish Gynecologic Oncology Group Study (TRSGO-SLN-005)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04714931
Enrollment
200
Registered
2021-01-20
Start date
2021-01-01
Completion date
2022-04-01
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer, Sentinel Lymph Node

Brief summary

The aim of the study to evaluate the feasibility and accuracy of sentinel lymph node technique in ovarian cancer.

Detailed description

Systematic pelvic and paraaortic lymphadenectomy is commonly performed in ovarian cancer patients. However, in early ovarian cancer systematic lymphadenectomy can be an unnecessary procedure which can cause perioperative morbidity and mortality. In the other hand, initially diagnosed early stage ovarian cancer can be upstaged after staging surgery with systematic lymphadenectomy. For preventing unnecessary lymphadenectomy in early ovarian cancer, sentinel lymph node procedure may be an alternative which can prevent major complications without missing the real stage of the disease. Aim of our study is to assess the feasibility and accuracy of lymph node evaluation with sentinel lymph node technique in early ovarian cancer patients. Pelvic and paraaortic spaces will be evaluated for the sentinel lymph nodes after the injection of the tracers in infundibulopelvic and utero-ovarian ligaments. Than routine systematic pelvic and paraaortic lymphadenectomy will be performed with the routine practice.

Interventions

Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.

Sponsors

Acibadem University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Prospective, Controlled, not randomized

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Early stage ovarian cancer

Exclusion criteria

* Patient who had been administrated chemotherapy prior to surgery * Patients who had diagnosed with malignancy other than ovarian cancer. * Patients who had undergone pelvic or paraaortic lymphadenectomy or surgery prior to surgery. * Patients who have allergy for the tracers.

Design outcomes

Primary

MeasureTime frameDescription
Sentinel lymph node localization12 monthsLocalization areas of pelvic and paraaortic sentinel lymph nodes for ovarian cancer will be identified.
Sentinel lymph node technique accuracy in ovarian cancer12 monthsSensitivity and specificity measure of the sentinel lymph node procedure in ovarian cancer for detecting the lymphatic metastasis
PPV and NPV of sentinel lymph node procedure in ovarian cancer12 monthsPositive predictive and negative predictive value of sentinel lymph node procedure in ovarian cancer.
Adverse events12 monthsAdverse events related with sentinel lymph node procedure in ovarian cancer
Sentinel lymph node detection rate12 monthsPelvic and paraaortic Sentinel lymph node detection rates will be assessed for ovarian cancer.

Secondary

MeasureTime frameDescription
Tracer comparisons12 monthsDetection rate differences between different tracers
Assessment of the sentinel tecniques12 monthsEvaluation of the tracer injection techniques whether before the excision of the mass or after the excision of the mass for the effectiveness of sentinel lymph node detection.

Countries

Turkey (Türkiye)

Contacts

Primary ContactOzguc Takmaz, Assist.Prof
ozguctakmaz@hotmail.com+905554006591

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026